Yi Chai1, Wei Liu1, Caixia Wang2, Minchao Rao3, Yuqi Zhang4,5. 1. School of Clinical Medicine and Department of Neurosurgery, Yuquan Hospital, School of Clinical Medicine, Tsinghua University, Beijing, China. 2. School of General Practice and Continuing Education, Capital Medical University, Beijing, China. 3. Department of Oncology, Shangrao People Hospital, Shangrao, Jiangxi, China. 4. School of Clinical Medicine and Department of Neurosurgery, Yuquan Hospital, School of Clinical Medicine, Tsinghua University, Beijing, China. doctorzyq@126.com. 5. Department of Neurosurgery, Yuquan Hospital, Tsinghua University, No. 5 Shijingshan Road, Shijingshan District, Beijing, 100040, China. doctorzyq@126.com.
Abstract
BACKGROUND: Chicken ovalbumin upstream promoter transcription factor II is known to play a crucial role in the tumor microenvironment. However, the role of NR2F2 in gliomas is unknown. METHODS: The genomic and clinical data of 530 cases of lower grade gliomas (LGGs) patients and 167 cases of glioblastoma (GBM) patients in The Cancer Genome Atlas (TCGA) were extracted for analysis. R2 and UCSC Xena browser were used for Kaplan-Meier survival in the GSE16011 dataset and TCGA dataset, respectively. GraphPad Prism 7 was used to compare the differences in NR2F2 expression between various groups and subtypes. RESULTS: LGG patients with low NR2F2 expression had a significantly favorable outcome compared with those with high NR2F2 expression (p < 0.05). By matching histological subtypes and gene expression profiles of LGG patients, grade II glioma group showed lowest levels of NR2F2 expression compared with grade III gliomas and GBM. Patients diagnosed with astrocytoma have highest expression of NR2F2 but lowest OS (p < 0.05). In LGGs, NR2F2 expression was significantly downregulated in patient group with IDH mutation and 1p19q co-deletion (p < 0.05). CONCLUSION: Our study suggests that NR2F2 can be used as a prognostic marker in LGG patients with IDH mutation and 1p19 co-deletion.
BACKGROUND: Chicken ovalbumin upstream promoter transcription factor II is known to play a crucial role in the tumor microenvironment. However, the role of NR2F2 in gliomas is unknown. METHODS: The genomic and clinical data of 530 cases of lower grade gliomas (LGGs) patients and 167 cases of glioblastoma (GBM) patients in The Cancer Genome Atlas (TCGA) were extracted for analysis. R2 and UCSC Xena browser were used for Kaplan-Meier survival in the GSE16011 dataset and TCGA dataset, respectively. GraphPad Prism 7 was used to compare the differences in NR2F2 expression between various groups and subtypes. RESULTS: LGG patients with low NR2F2 expression had a significantly favorable outcome compared with those with high NR2F2 expression (p < 0.05). By matching histological subtypes and gene expression profiles of LGG patients, grade II glioma group showed lowest levels of NR2F2 expression compared with grade III gliomas and GBM. Patients diagnosed with astrocytoma have highest expression of NR2F2 but lowest OS (p < 0.05). In LGGs, NR2F2 expression was significantly downregulated in patient group with IDH mutation and 1p19q co-deletion (p < 0.05). CONCLUSION: Our study suggests that NR2F2 can be used as a prognostic marker in LGG patients with IDH mutation and 1p19 co-deletion.
Authors: Lenny Dang; David W White; Stefan Gross; Bryson D Bennett; Mark A Bittinger; Edward M Driggers; Valeria R Fantin; Hyun Gyung Jang; Shengfang Jin; Marie C Keenan; Kevin M Marks; Robert M Prins; Patrick S Ward; Katharine E Yen; Linda M Liau; Joshua D Rabinowitz; Lewis C Cantley; Craig B Thompson; Matthew G Vander Heiden; Shinsan M Su Journal: Nature Date: 2009-12-10 Impact factor: 49.962
Authors: Lonneke A M Gravendeel; Mathilde C M Kouwenhoven; Olivier Gevaert; Johan J de Rooi; Andrew P Stubbs; J Elza Duijm; Anneleen Daemen; Fonnet E Bleeker; Linda B C Bralten; Nanne K Kloosterhof; Bart De Moor; Paul H C Eilers; Peter J van der Spek; Johan M Kros; Peter A E Sillevis Smitt; Martin J van den Bent; Pim J French Journal: Cancer Res Date: 2009-11-17 Impact factor: 12.701
Authors: Michele Ceccarelli; Floris P Barthel; Tathiane M Malta; Thais S Sabedot; Sofie R Salama; Bradley A Murray; Olena Morozova; Yulia Newton; Amie Radenbaugh; Stefano M Pagnotta; Samreen Anjum; Jiguang Wang; Ganiraju Manyam; Pietro Zoppoli; Shiyun Ling; Arjun A Rao; Mia Grifford; Andrew D Cherniack; Hailei Zhang; Laila Poisson; Carlos Gilberto Carlotti; Daniela Pretti da Cunha Tirapelli; Arvind Rao; Tom Mikkelsen; Ching C Lau; W K Alfred Yung; Raul Rabadan; Jason Huse; Daniel J Brat; Norman L Lehman; Jill S Barnholtz-Sloan; Siyuan Zheng; Kenneth Hess; Ganesh Rao; Matthew Meyerson; Rameen Beroukhim; Lee Cooper; Rehan Akbani; Margaret Wrensch; David Haussler; Kenneth D Aldape; Peter W Laird; David H Gutmann; Houtan Noushmehr; Antonio Iavarone; Roel G W Verhaak Journal: Cell Date: 2016-01-28 Impact factor: 41.582
Authors: Maria E Figueroa; Omar Abdel-Wahab; Chao Lu; Patrick S Ward; Jay Patel; Alan Shih; Yushan Li; Neha Bhagwat; Aparna Vasanthakumar; Hugo F Fernandez; Martin S Tallman; Zhuoxin Sun; Kristy Wolniak; Justine K Peeters; Wei Liu; Sung E Choe; Valeria R Fantin; Elisabeth Paietta; Bob Löwenberg; Jonathan D Licht; Lucy A Godley; Ruud Delwel; Peter J M Valk; Craig B Thompson; Ross L Levine; Ari Melnick Journal: Cancer Cell Date: 2010-12-09 Impact factor: 38.585